Sulfamethizole

• Catalog No.: DB00576
• CAS Number: 144-82-1
• M. F.: C9H10N4O2S2
• M. W.: 270.3313

SYNONYMS

• IUPAC name: 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzene-1-sulfonamide
• IUPAC Traditional name: sulfamethizole
• Brand Name: Lucosil; Solfametizolo [Dcit]; Thiosulfil; Rufol; Ultrasul; Urodiaton; Sulfapyelon; Tetracid; Urosulfin; Ayerlucil; Methazol; Proklar; Sulfamethiazole; Sulamethizole; Sulfamethizol; Sulfamethizole [Usan:Inn:Jan]; Sulfamethizolum [INN-Latin]; Sulfamethylthiadiazole; Sulfametizol [INN-Spanish]; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Thidicur; Thiosulfil Forte; Urocydal; Urolucosil; Uroz; Famet; Microsul; Renasul; Salimol; Sulfa Gram; Sulfamethazole

DATABASE IDS

• CAS Number: 144-82-1
• PubChem CID: 5328
• PubChem SID: 46508656

PROPERTIES

• Hydrophobicity(logP): 0.9
• Solubility: 1050 mg/L

DETAILS

Description (English)

• Drug Groups: approved
• Description: A sulfathiazole antibacterial agent. [PubChem]
• Indication: For the treatment of urinary tract infection
• Pharmacology: Sulfamethizole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
• Affected Organisms: Enteric bacteria and other eubacteria
• Biotransformation: Hepatic.
• Absorption: Rapidly absorbed.
• Half Life: 3-8 hours
• Protein Binding: 98-99%
• References: Ratanajamit C, Skriver MV, Norgaard M, Jepsen P, Schonheyder HC, Sorensen HT: Adverse pregnancy outcome in users of sulfamethizole during pregnancy: a population-based observational study. J Antimicrob Chemother. 2003 Nov;52(5):837-41. Epub 2003 Sep 30. [Pubmed] ; Kerrn MB, Frimodt-Moller N, Espersen F: Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model. Antimicrob Agents Chemother. 2003 Mar;47(3):1002-9. [Pubmed] ; Watanabe H, Hastings JW: Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34. [Pubmed]
• External Links: Wikipedia

REFERENCES

• Ratanajamit C, Skriver MV, Norgaard M, Jepsen P, Schonheyder HC, Sorensen HT: Adverse pregnancy outcome in users of sulfamethizole during pregnancy: a population-based observational study. J Antimicrob Chemother. 2003 Nov;52(5):837-41. Epub 2003 Sep 30. Pubmed
• Kerrn MB, Frimodt-Moller N, Espersen F: Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model. Antimicrob Agents Chemother. 2003 Mar;47(3):1002-9. Pubmed
• Watanabe H, Hastings JW: Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34. Pubmed